DR
DRMAW
Dermata Therapeutics, Inc.
$0.0183
0.00%
$55.1K
No data for this timeframe.
Vol
Market Cap$55.1K
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$22.00
Inst. Activity0 buys / 1 sells
SEC Reports3
Recent Activity
Jun 1, 2026
SEC
The SEC declared effective Dermata Therapeutics' S-3 shelf registration (File No. 333-291740) on May 29, 2026, allowing
EFFECT — Impact 6/10
May 27, 2026
SEC
Dermata Therapeutics held its 2026 Annual Meeting on May 27, 2026. Stockholders approved several proposals including the
8-K — Impact 3/10
Apr 17, 2026
SEC
Analysis based on filing metadata only — document content was unavailable
DEFA14A — Impact 3/10
Inst.
UBS Group AG — TRIM
1,279 shares ($22.00)
Inst.
UBS Group AG — TRIM
1,880 shares ($34.00)
Latest Reports
BEARISH
EFFECT
6/10
The SEC declared effective Dermata Therapeutics' S-3 shelf registration (File No. 333-291740) on May 29, 2026, allowing
Jun 1, 2026
NEUTRAL
8-K
3/10
Dermata Therapeutics held its 2026 Annual Meeting on May 27, 2026. Stockholders approved several proposals including the
May 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| UBS Group AG | $22.00 | TRIM |
1 institutional holders with $22.00 total value (1,279 shares) as of 2025-Q3. Top holders: UBS. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 1,279 | $22.00 | 100.0% | TRIM -32.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | TRIM | 1,880 | 1,279 | -32.0% | $22.00 | 2025-Q3 |
| UBS Group AG | TRIM | 2,617 | 1,880 | -28.2% | $34.00 | 2025-Q2 |
| UBS Group AG | TRIM | 4,142 | 2,617 | -36.8% | $44.00 | 2025-Q1 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 4.0/10.
BEARISH
EFFECT
6/10
The SEC declared effective Dermata Therapeutics' S-3 shelf registration (File No. 333-291740) on May
Jun 1, 2026
NEUTRAL
8-K
3/10
Dermata Therapeutics held its 2026 Annual Meeting on May 27, 2026. Stockholders approved several pro
May 27, 2026
NEUTRAL
DEFA14A
3/10
Analysis based on filing metadata only — document content was unavailable
Apr 17, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 650.0% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.